Trading Sections
AtaiBeckley: Canaccord Raises Target to $17 and Praises Progress in DMT Buccal Film Study!
The biopharma sector continues to experience steady interest in companies dedicated to developing novel...
Arcturus Therapeutics: Strategic Focus on Rare Diseases and Thermo Fisher Alliance Bring mRNA Specialists into Analyst Spotlight
Arcturus secures industry giant Thermo Fisher Scientific as a strategic partner for the phase 3 development...
Nemetschek: AI initiatives and M&A strategy underpin analyst price target of 110 euros
US bank JPMorgan maintains the Nemetschek stock rating at "Overweight" after a recent management discussion,...
Larimar Therapeutics aims to file BLA for Nomlabofusp: H.C. Wainwright expects market launch in 2027 and billion-dollar revenue
H.C. Wainwright begins coverage of the Larimar stock with a "Buy" recommendation and a price target of...
Grindr Inc.: Strategic Shift with "Edge" and "Woodwork" – Morgan Stanley Sees Peak Price Target of $29!
Grindr Inc. (GRND) operates a globally established social network for the LGBTQ+ community. The core...
Viridian Therapeutics: Advances in the TED Pipeline Support Analyst Price Targets of up to $43!
Wall Street is responding with significant price target increases to the operational developments at...
Roblox: After 67% Price Decline, Research Firm Arete Issues a Buy Recommendation - Experts See New Upside Potential Through AI Safety Features and Advertising Revenues
The research firm Arete has upgraded the Roblox stock rating from "Neutral" to "Buy" following a significant...
Eupraxia Pharmaceuticals: How Targeted Drug Release Addresses Billion-Dollar Markets – Oppenheimer Sees Massive Price Potential
From Systemic to Local Therapy: The Business Model Eupraxia Pharmaceuticals Inc. (EPRX) is a clinical-stage...
Bitdeer Technologies: Realignment to High-Performance Computing for AI Workloads Boosts Analyst Expectations – Price Target at $35
From Crypto Miner to Vertically Integrated Infrastructure Provider The Bitdeer Technologies Group...
Tenax Therapeutics Approaching Crucial Study Data: Experts See High Potential in the Cardiopulmonary Portfolio
Tenax Therapeutics (TENX) is a biopharmaceutical company in clinical phase 3, focused on the identification...
SpaceX: How Starlink V3 and Starship Successes Elevate the Company to a New Level - Arete Sees 124% Price Potential
SpaceX (SPCX) launched on June 12th under the ticker SPCX with a historic valuation of around 1.78 trillion...
Immix Biopharma: Convincing CAR-T Study Data and $2 Billion Revenue Potential Bring Focus to Stock
The Business Model and Breakthrough in Cell Therapy Immix Biopharma (IMMX) is a clinical biopharmaceutical...
Nano Nuclear Energy: With Strategic Acquisitions and AI Excitement Towards a Vertically Integrated Nuclear Future - Experts See 87% Price Potential
The renaissance of nuclear energy in global financial markets is in full swing. While traditional large...
Camp4 Therapeutics: JPMorgan Upgrade and Progress on CMP-002 Highlight RNA Pioneer
The Business Model of Targeted Gene Upregulation Camp4 Therapeutics (CAMP) is a biopharmaceutical...
Rezolute: Pipeline Progress and Buy Recommendation from Guggenheim with the Addition as "Best Idea"
The Business Model: Innovation in Rare Metabolic Diseases Rezolute (RZLT) is a clinical-stage biopharmaceutical...
Avalo Therapeutics: Phase-2 Success and Fresh Capital Fuel Biotech Hope - BofA Recommends Buy with Target of $35!
Focus on Unmet Medical Needs Avalo Therapeutics (AVTX) presents itself in the current biotech landscape...
Rigetti Computing: 108-Qubit Milestone and $100 Million Funding Drive $40 Price Target Spark Buy Interest!
Government Mandate: The US Department of Commerce signed a memorandum of understanding in May 2026...
AnaptysBio as a Pure Royalty Manager: Jemperli Dynamics and the Overlooked Imsidolimab Potential Justify $95 Price Target
AnaptysBio (ANAB) underwent a massive structural transformation in spring 2026 and now offers investors...
FuelCell: Transformative Data Center Deals Within Reach Following Canaccord Upgrade
FuelCell: Transformative Data Center Deals Within Reach Following Canaccord Upgrade Quarterly Results...
GMR Solutions: Goldman Sachs Sees 221% Price Potential - Defensive Character and Underestimated Growth Praised!
A Branch Giant with Growth Potential GMR Solutions Inc. (GMRS) presents itself as the leading provider...
Coya Therapeutics: Treg Therapy COYA 302 on Track for ALS Approval and $2.2 Billion Revenue Potential
Current Milestones and Corporate Developments Coya Therapeutics (COYA) has made significant operational...
Rezolute: Breakthrough in Phase 3 Study Opens Transformation to a Commercial Biotech Player - Maxim Sees 222% Price Potential for the Stock!
The release of convincing interim data from the Phase 3 clinical study "upLIFT" has brought the stock...
Red Cat Holdings: Billion-Dollar Capacities and New NATO Contracts Fuel Breakout Growth - Roth Capital Sees Nearly 70% Price Potential
Strategic Milestones and Massive Production Scaling Red Cat Holdings (RCAT) (i.) looks back on extremely...